

# FORM 7

## MONTHLY PROGRESS REPORT

Name of Listed Issuer: AREV Life Sciences Global Corp. (“AREV” or the “Issuer”).

Trading Symbol: AREV

Number of Outstanding Listed Securities: 28,533,807

Date: March 2022

### Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECCanada and The Biotechnology Innovation Organization (BIO).

2. Provide a general overview and discussion of the activities of management.

**During the month of March 2022** the Company was pleased to announce it has engaged the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN”, AREV’s next generation Ready to Use Therapeutic Food (RUTF.)

AREV, through its US subsidiary in Rochester NY, is developing the next generation, aflatoxin free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives of several academic research institutions, including the Institute for Human Virology (IHV), The Linus Pauling Institute (LPI) at Oregon State University (OSU) and the Richardson Centre for Functional Foods and Nutraceuticals “RCFFN” at the University of Manitoba.

The agreement dated, March 2, 2022, for RCFFN to assist in the design and formulation of a next generation truly therapeutic Ready to Use Therapeutic Food “RUTF”. The project will be composed in two stages:

1. To research and propose 3 RUTF formulations for the client to consider, factoring in optimal amino acid content, fibre, fat, taste, cost and caloric build.
2. Once a RUTF is selected, RCFFN will prepare small batches of the RUTF in the RCFFN Commercial Kitchen.

AREV’s **SUSTAINN** addresses the clinical causes of SAM and inanition which facilitate disease progression including dysbiosis, environmental enteropathy, elevated inflammation, and immune dysfunction that are associated with increased morbidity and mortality in key populations affected by disease progression as substantiated in multiple peer-review publications. SUSTAINN is being developed to meet and exceed guidance set forth by public health commodity procurement programs such as USAID and UNICEF. The design is in accordance with the World Health Organization (WHO) Global Action Plan (GAP) for Child Wasting Guidelines published March 2021 and the UNICEF RUTF Procurement Guidance, published April 2021. The information in the WHO and UNICEF guidelines support the UN Millennium Development Goals (MDG’s) identified at the 2021 Nutrition for Growth (N4G), summit held in Tokyo, which demonstrates definitive clinical affect with attribution of mechanisms of action for a diverse cost-effective intervention in patient populations in low- and middle-income countries dependent on global health commodity distribution through implementing Non-Government Organizations (NGO).

*“AREV’s development of SUSATAINN is now being enhanced by this collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba” said Dr. Roscoe Moore, Chairman of the Scientific Advisory Board for AREV Life Sciences, and Board Member of Global Virus Network. He went on to say, “Our product development and research from Linus Pauling Institute has provided the initial data to be applied with the scientists at The Richardson Centre for Functional Foods and Nutraceuticals in order to accelerate the introduction of SUSTAINN into public health commodity procurement program utilization to combat global famine and serious and acute*

malnutrition during the intersection of COVID-19 and other pandemic infections that are driving a global decline of life expectancy and childhood mortality.”

“We are excited to collaborate with AREV Life Sciences on this innovative product development project benefiting global public health. The development of SUSTAINN as a healthy, nourishing RUTF at a low-cost has the potential to bring significant nutritional value to populations experiencing famine.” stated Michael Janzen, PhD, Research Development Manager, University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals.

The invasion of Ukraine comes at a time when the complete collapse of food security in Ethiopia, (Source <https://www.mercycorps.org/blog/fighting-hunger-ethiopia>) Venezuela ( Source <https://www.frontiersin.org/articles/10.3389/fsufs.2021.635981/full> ) and Afghanistan ( source <https://www.orfonline.org/research/the-crisis-of-food-insecurity-in-afghanistan/> ) places tens of millions at further risk of malnutrition and starvation. The recent introduction of the Global Malnutrition Prevention and Treatment Act (S.2956/H.R.4693), led by Senators Christopher Coons (D-DE), and Representative Gregory Meeks (D-NY) Chair of the House Committee for Foreign Affairs and USAID, America’s international development agency, to support countries to address global famine by increasing coverage for high impact, proven and affordable interventions, including research on next generation therapeutic foods to treat severe acute malnutrition (SAM ) that now is the leading cause of death of children worldwide and accounting for more than three million deaths annually and expected to exponentially increase in 2022. AREV’s collaboration with the RCFN accelerates bringing SUSTAINN to the marketplace and in conjunction with other efforts by our academic partners so AREV can clearly demonstrate the clinical efficacy of our next generation RUTF.

More than two million people from Ukraine are now refugees and the UN is predicting 5 to 6 million more Ukrainians to flee as the conflict escalates, (source <https://www.bbc.com/news/world-60555472>) the majority being women and children to enter in neighbouring EU countries which have committed to unprecedented levels of humanitarian assistance for both refugees as well as those besieged in the conflict zone within the first week of the conflict. More than half of the one million Ukrainian refugees are children, according to Philippe Cori, UNICEF’s Deputy Regional Director for Europe and Central Asia. Those leaving Ukraine are mostly women and children. “The situation for children in Ukraine is getting worse by the minute. Children are being killed and injured. 7.5 million children are at risk,” Cori warned at a press conference in Paris on Thursday (3 March).

The Eleanor Crook Foundation, a recognized global policy leader in malnutrition and famine is on the record for their analysis of the current policies exacerbating the global famine “The scale of the problem is immense, but proven interventions to prevent and treat malnutrition are considered some of the most cost-effective solutions in global health and development.” (source <https://eleanorcrookfoundation.org/>).

In a United Nations published report dated November 2021 on Global Action Plan (GAP) for Child Wasting ( source <https://www.childwasting.org/> ). Key priority food action includes, strict quality assurance (QA) standards. Guarantee the safety and quality standards of locally produced specialized nutritious foods necessary for the treatment of child wasting. This can be achieved through better collaboration with the private sector and support efforts to prevent and reduce aflatoxin and other toxins in therapeutic foods.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**NONE.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**NONE.**

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**NONE.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- NONE.**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
- NONE.**
8. Describe the acquisition of new customers or loss of customers.
- NONE.**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.
- NONE.**
10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.
- NONE.**
11. Report on any labour disputes and resolutions of those disputes if applicable.
- NONE.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
- NONE.**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
- NONE.**
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.  
n/a.
16. Provide details of any changes in directors, officers or committee members.  
**NONE.**
17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2020. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at [www.sedar.com](http://www.sedar.com).


## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 5, 2022.

Mike Withrow  
Name of Director or Senior Officer

  
\_\_\_\_\_  
Signature  
CEO & Director  
\_\_\_\_\_  
Official Capacity

<b>Issuer Details</b> Name of Issuer AREV Life Sciences Global Corp.	For Month End March 2022	Date of Report YYYY/MM/DD 2022/04/05
Issuer Address Unit 18 – 91 Golden Drive		
City/Province/Postal Code Coquitlam, BC, V3K 6R2	Issuer Fax No. ( ) n/a	Issuer Telephone No. (604) 803-8439
Contact Name Denby Greenslade	Contact Position Corporate Secretary	Contact Telephone No. (604) 803-8439
Contact Email Address denby@arevbrands.com	Web Site Address www.arevlifesciences.com	